GlassScriptPhysician profile
Michael D Rua
NPI 1851321574
$17,877.11
in general payments reported to CMS, 2019-2025
56 companies · $2,735 in 2025
The $2,735 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,152 · 2022: $3,661 · 2023: $3,364 · 2024: $3,965 · 2025: $2,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $29.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,034.45 |
| Education | $29.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,210.22 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,647.91 | 2021-2025 | Farxiga, Airsupra, Fasenra |
| Abbvie INC. | $1,623.08 | 2021-2025 | |
| Lilly USA, LLC | $1,586.19 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,397.81 | 2021-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $1,286.72 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,228.60 | 2021-2025 | |
| Amgen INC. | $652.19 | 2021-2025 | Tezspire, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $646.32 | 2021-2025 | |
| Amarin Pharma, INC. | $514.93 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $470.45 | 2021-2025 | Spravato, Xarelto |
| Sanofi-Aventis U.S. LLC | $273.21 | 2021-2025 | |
| Exact Sciences Corporation | $269.68 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Shield Therapeutics INC | $268.97 | 2023-2024 | Accrufer |
| Averitas Pharma INC. | $268.54 | 2023-2025 | Qutenza |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.